Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation
The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of severe life-threatening autoimmune diseases, and one of the most important problems in practical rheumatology. This article discusses 2021 American College of Rheumatology/Vasculitis Foundation guideline fo...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2021-12-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3102 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850043050104979456 |
|---|---|
| author | T. V. Beketova I. Yu. Popov V. V. Babak |
| author_facet | T. V. Beketova I. Yu. Popov V. V. Babak |
| author_sort | T. V. Beketova |
| collection | DOAJ |
| description | The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of severe life-threatening autoimmune diseases, and one of the most important problems in practical rheumatology. This article discusses 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of AAVs, including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). The guideline features 26 recommendations and 5 upgraded position statements for GPA/ MPA, as well as 15 recommendations and 5 upgraded position statements for EGPA, which became the basis for the proposed algorithms for the treatment of patients with GPA/MPA and EGPA. Particular attention has been paid to the use of biologics. |
| format | Article |
| id | doaj-art-8ced109ce6284ef99b141d8683363a5f |
| institution | DOAJ |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2021-12-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-8ced109ce6284ef99b141d8683363a5f2025-08-20T02:55:20ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922021-12-0159668469210.47360/1995-4484-2021-684-6922766Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis FoundationT. V. Beketova0I. Yu. Popov1V. V. Babak2V.A. Nasonova Research Institute of Rheumatology; Central Clinical Hospital of the Administrative Directorate of the President of the Russian FederationV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyThe anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of severe life-threatening autoimmune diseases, and one of the most important problems in practical rheumatology. This article discusses 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of AAVs, including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). The guideline features 26 recommendations and 5 upgraded position statements for GPA/ MPA, as well as 15 recommendations and 5 upgraded position statements for EGPA, which became the basis for the proposed algorithms for the treatment of patients with GPA/MPA and EGPA. Particular attention has been paid to the use of biologics.https://rsp.mediar-press.net/rsp/article/view/3102systemic vasculitisantineutrophil cytoplasmic antibodiesgranulomatosis with polyangiitis (wegener's)microscopic polyangiitiseosinophilic granulomatosis with polyangiitisrituximab |
| spellingShingle | T. V. Beketova I. Yu. Popov V. V. Babak Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation Научно-практическая ревматология systemic vasculitis antineutrophil cytoplasmic antibodies granulomatosis with polyangiitis (wegener's) microscopic polyangiitis eosinophilic granulomatosis with polyangiitis rituximab |
| title | Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation |
| title_full | Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation |
| title_fullStr | Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation |
| title_full_unstemmed | Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation |
| title_short | Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation |
| title_sort | review of guideline for the management of anca associated vasculitis presented in 2021 by the american college of rheumatology vasculitis foundation |
| topic | systemic vasculitis antineutrophil cytoplasmic antibodies granulomatosis with polyangiitis (wegener's) microscopic polyangiitis eosinophilic granulomatosis with polyangiitis rituximab |
| url | https://rsp.mediar-press.net/rsp/article/view/3102 |
| work_keys_str_mv | AT tvbeketova reviewofguidelineforthemanagementofancaassociatedvasculitispresentedin2021bytheamericancollegeofrheumatologyvasculitisfoundation AT iyupopov reviewofguidelineforthemanagementofancaassociatedvasculitispresentedin2021bytheamericancollegeofrheumatologyvasculitisfoundation AT vvbabak reviewofguidelineforthemanagementofancaassociatedvasculitispresentedin2021bytheamericancollegeofrheumatologyvasculitisfoundation |